Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 7 months ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Heterogeneous Populations

Prevention & Chronic Conditions
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
Prof Nicolas Van Mieghem and Dr Joost Daemen interprets the findings from the top 10 ACC.23/WCC late-breaking and featured science trials and studies in their critical View from the Thoraxcenter review series. Join them as they consider the implications for research and offer an insight into how they will incorporate the latest data into their day-to-day clinical practice. What are the top… View more

Vascular Disease and Surgery

Standards & Guidelines
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
Author(s): Christie Ballantyne Added: 1 year ago
ACC.23/WCC—We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C)… View more

Prevention & Chronic Conditions
Christie Ballantyne
Job title: Chief of Cardiovascular Research and Director of the Center for Cardiometabolic Disease Prevention
Dr Christie Ballantyne is the Chief of Cardiovascular Research,Director of the Center for Cardiometabolic Disease Prevention, and Professor of Medicine atBaylor College of Medicine in Texas, US. He received his MD from Baylor College of Medicine and performed both his internal medicine residency at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at… View more
ECR Nicholls
Author(s): Stephen J Nicholls Added: 3 years ago
Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop… View more

Prevention & Chronic Conditions
View from the Thoraxcenter: What's Hot at ACC.23?
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
Prof Nicolas Van Mieghem and Dr Joost Daemen return with their critical review series, View from the Thoraxcenter, to preview the most anticipated late-breaking and featured science trials of ACC.23. Which trials have the potential to change practice? What are the key considerations for patient care and research? What is the context of the top trials of ACC? Trials covered in detail include: … View more

Prevention & Chronic Conditions

Intervention
ACC 2023: Late-Breaking Science Video Collection
Author(s): Enoch Akowuah , Annapoorna Kini , Atul Verma , et al Added: 1 year ago
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen(Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall(McMaster University, Hamilton, CA)… View more

Standards & Guidelines

Heart Failure
Author(s): Antoni Martínez-Rubio , Román Freixa Pamias Added: 3 years ago
Hypercholesterolemia has been known for several years to be a major risk factor in the development of atherosclerosis and consecutively cardiovascular disease. This epidemiological concept has been widely confirmed using different strategies that have reduced low-density lipoprotein (LDL) levels and cardiovascular events (morbidity and mortality) in primary as well as in secondary prevention, in… View more

Prevention & Chronic Conditions

Demographic
ESC 23: Hot Line & Late-breaking Science Video Collection
Author(s): Yugo Yamashita Added: 8 months ago
What's hot at the European Society of Cardiology (ESC) Congress 2023? Browse our curated coverage of the latest updates in cardiology from Amsterdam. Watch ourView From the Thoraxcenterseries for a concise line up of the most awaited trials fromProf Nicolas Van MieghemandDr Joost Daemen. For a deeper dive into key clinical trial data and its applicability, host,Dr Harriette Van… View more

Anticoagulation

Standards & Guidelines
Author(s): Koji Hasegawa Added: 3 years ago
Myocardial infarction is often caused by the rupture of unstable plaque in atherosclerosis with mild-to-moderate stenosis. Research has revealed that local tissue inflammation is closely involved in the rupture of atherosclerotic plaque.1 Stabilization of atherosclerotic plaque by strictly managing the risk factors for coronary artery disease is a crucial strategy to prevent the recurrence of… View more

Heart Failure

Prevention & Chronic Conditions